Effective treatment of advanced Hodgkin lymphoma with a modified BEACOPP regimen for a patient with demyelinating hereditary motor and sensory neuropathy type 1 (HMSN1)

Patrick P Hess; Monica S Ventura Ferreira; Benjamin Rolles; Martin Kirschner; Florian Holtbernd; Mareike Tometten; Tim H Brümmendorf; Fabian Beier

doi:10.1002/ccr3.5766

Effective treatment of advanced Hodgkin lymphoma with a modified BEACOPP regimen for a patient with demyelinating hereditary motor and sensory neuropathy type 1 (HMSN1)

Clin Case Rep. 2022 May 5;10(5):e05766. doi: 10.1002/ccr3.5766. eCollection 2022 May.

Authors

Patrick P Hess^{1

2}, Monica S Ventura Ferreira^{1

2}, Benjamin Rolles^{1

2}, Martin Kirschner^{1

2}, Florian Holtbernd³, Mareike Tometten^{1

2}, Tim H Brümmendorf^{1

2}, Fabian Beier^{1

2}

Affiliations

¹ Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation RWTH Aachen University Aachen Germany.
² Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD) Aachen Germany.
³ Department of Neurology Medical Faculty RWTH Aachen University Aachen Germany.

Abstract

Treatment for Hodgkin lymphoma (HL) in adults comprises substantial risk of chemotherapy-induced peripheral neurotoxicity. Here, we describe the case of patient with Charcot-Marie-Tooth disease or HSMN1 and advanced Hodgkin lymphoma undergoing treatment with modified BEACOPP achieving complete remission without major aggravation of neurological symptoms.

Keywords: Hodgkin; hematology; lymphoma; neurology; neuropathy.

Publication types

Case Reports